Crescita Therapeutics Inc.
CRRTF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.11 | 0.01 | -0.09 | 0.00 |
| FCF Yield | 12.38% | 26.39% | -9.28% | -14.59% |
| EV / EBITDA | -3.00 | 1.71 | 3.42 | 8.01 |
| Quality | ||||
| ROIC | -19.12% | -12.59% | 4.94% | -3.34% |
| Gross Margin | 49.07% | 59.15% | 56.03% | 59.72% |
| Cash Conversion Ratio | -0.99 | -1.05 | -1.18 | 1.45 |
| Growth | ||||
| Revenue 3-Year CAGR | -5.94% | 1.47% | 14.58% | -9.11% |
| Free Cash Flow Growth | -20.74% | 255.56% | 35.72% | -135.02% |
| Safety | ||||
| Net Debt / EBITDA | 6.33 | 18.07 | -3.31 | -13.97 |
| Interest Coverage | -49.46 | -23.01 | 3.35 | -3.05 |
| Efficiency | ||||
| Inventory Turnover | 2.46 | 1.17 | 1.83 | 1.54 |
| Cash Conversion Cycle | -5.08 | 149.59 | 98.74 | 31.04 |